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ABSTRACT 
Use of induced hypothermia for the purpose of lowering intracranial pressure and 
preserving neuronal function has increased as research data reveals a trend of positive outcomes 
in patients treated with this therapy. Recently induced hypothermia following cardiac arrest due 
to ventricular fibrillation has been deemed successful. Current research has expanded to evaluate 
the effectiveness of induced hypothermia as a treatment modality for severe stroke and head 
trauma. In spite of its efficacy, complications exist with this treatment modality. The purpose of 
this literature review is to examine potential complications secondary to induced hypothermia 
and highlight the nurse’s role in managing patient care. At the present, patient protocols for 
induced hypothermia are lacking. The success of treatment is largely dependent on the skill of 
the healthcare team to prevent further harm and enhance therapeutic outcomes by providing 
astute assessment and management of complications in patients undergoing induced 
hypothermia. The desired outcome of this review is to promote integration of research in the 
development of evidence-based protocols for induced hypothermia. 
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CHAPTER ONE: Introduction 
Background 
Cardiac arrest, stroke, and head trauma may lead to compromised cerebral perfusion. 
Ischemia in the brain triggers an inflammatory response resulting in cerebral damage. 
Compensatory mechanisms rapidly exhaust oxygen reserves, and the brain transitions into a state 
of anaerobic metabolism for survival (McKean, 2009). Anaerobic metabolism in response to 
ischemia precipitates a state of acidosis, which leads to disintegration of cell membranes and cell 
death (Finkelstein & Alam, 2010). Initiating a state of hypothermia in ischemic situations is 
believed to decrease the metabolic rate and lower cerebral oxygen demands. Animal studies have 
shown that a reduction in body temperature decreases the activity of sodium-potassium 
adenosine triphosphate synthase (ATPase) resulting in a conservation of adenosine triphosphate 
(ATP) (Finkelstein & Alam, 2010).  
In the 1950s, hypothermia was first studied as an approach to preventing neurological 
dysfunction during cardiac surgery. Animal studies were followed by human trials which largely 
replicated the evidence that induced hypothermia (IH) lowers intracranial pressure, contributes to 
improved neurological outcomes, and reduces mortality in populations at risk for neurological 
dysfunction from cerebral ischemia (Oddo, Schaller, Feihl, Ribordy, & Liaudet, 2006; Zeitzer, 
2005;  Zhi, Zhang, & Lin, 2003). In 2002, two landmark studies presented supporting evidence 
that IH was the intervention of choice to preserve neurologic function for patients in post-cardiac 
arrest (Safer & Kochanek, 2002; The Hypothermia after Cardiac Arrest Study Group, 2002). In 
addition to cardiac arrest, research has expanded to explore application of IH in cases of 
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traumatic brain injury, stroke, spinal cord injury, bacterial meningitis, and neonatal hypoxic-
ischemic encephalopathy (Finkelstein & Alam, 2010; Bernard & Buist, 2002).  
Problem 
Research study results point favorably toward ongoing use of IH. This treatment 
modality, however, encompasses a variety of complex variables that have the potential to 
adversely affect patient outcomes. The preemptive problem in guiding the care of these patients 
is the lack of evidence based protocols. Potential for rapid changes in patient condition and 
serious adverse effects require close monitoring by the nurse and the foreknowledge to anticipate 
needs and provide appropriate interventions. 
Adverse effects of IH include shivering, which increases metabolic demands and oxygen 
consumption, increased risk for infection, and decreased platelet count and function (McKean, 
2009; Finkelstein & Alam, 2010). Electrolyte imbalances, specifically hypokalemia, can develop 
rapidly during hypothermia and adversely affect heart rate and rhythm among other 
physiological functions (Finkelstein & Alam, 2010). Cardiovascular alterations, including 
bradycardia, hypotension, and dysrhythmias can further complicate the patient’s status. Risks 
during rewarming include rebound hyperthermia and increased intracranial pressure (ICP) 
(McKean, 2009).  
The complications associated with IH emphasize the importance of skilled nursing care 
and management for patients undergoing induced hypothermia. Development of evidence based 
protocols would promote patient safety by increasing awareness of complications and enhancing 
anticipation and management of patient needs.  
3 
 
Purpose 
The purpose of this thesis was to provide a review of research findings on the 
physiological complications of IH and implications for nursing practice. Use of IH is increasing, 
yet patient care protocols are lacking. By increasing nursing awareness, complications can be 
managed in a way that promotes optimal patient functioning following treatment. This literature 
review is designed to integrate research findings that may promote development of evidence 
based patient care protocols.  
Method 
A synthesis of current research on IH was conducted for this thesis. The databases 
selected for the literature review included CINAHL, Medline, and the Cochrane Database of 
Systematic Reviews. Induced hypothermia in adult populations with witnessed cardiac arrest and 
traumatic head injury were the target populations. However, other forms of neuronal insult were 
explored as well. Search terms used were induced hypothermia, therapeutic hypothermia, 
complications, effects, fluid and electrolyte imbalance, arrhythmias, dysrhythmias, and review. 
Dates of research studies focused on studies published between the years 2000-2010 and 
included peer-reviewed articles and those written in the English language. Studies conducted in 
the United States and internationally were used in the literature review. Neonates receiving 
treatment for encephalopathy and pediatric populations were excluded from this thesis to direct 
focus toward complication management in adult populations.  
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Pathophysiology 
 The control center for thermoregulation is the hypothalamus. Normal body temperature is 
maintained within a narrow range of 36.6° + 0.38°C to promote optimal metabolic function. 
Thermoreceptors located in the skin, hypothalamus, spinal cord, and abdominal organs provide 
feedback to the hypothalamus on the status of core and peripheral body temperature. Body heat, 
generated through metabolism and chemical thermogenesis, is distributed to all body tissues via 
the circulatory system. Limiting or increasing blood flow via vasoconstriction or vasodilation 
allows the body to regulate temperature, thereby maintaining a state of homeostasis (Polderman, 
2004). When the hypothalamus senses a drop in temperature, peripheral vasoconstriction occurs 
and blood is shunted to the core where heat can be retained. Cooler body temperatures result in 
increased muscle tone in the form of shivering and contribute to a rise in temperature by 
increasing metabolic rate (Huether & McCance, 2008). In contrast, vasodilation occurs when 
body temperature rises, thereby increasing the volume of blood that reaches peripheral 
circulation for cooling (Polderman, 2004). Hyperthermia accelerates the rate of cell damage. 
When body temperature reaches 41°C, nerve damage occurs resulting in convulsions and 
eventual death (Huether & McCance, 2008).  
Hypothermia decreases overall metabolic rate and specifically influences cerebral 
metabolic rate (Polderman, 2004). Desirable effects of hypothermia when ischemia and 
inflammation are present in the heart or brain are reduction in cellular oxygen demands and 
slowed rate of cellular death.  In fact, donor organs being preserved for transplantation are kept 
on ice until transplant for this very reason. The neuroprotective quality of hypothermia has 
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created interest in inducing hypothermia as a therapeutic option for protecting the heart and brain 
when ischemia is present (Polderman, 2004; Zhi, Zhang, & Lin, 2003).  
History of Induced Hypothermia 
 The first documented use of IH took place in 1937 on a cancer patient in an attempt to 
decrease the rate of metastatic cellular division. Results in this patient showed no change in the 
rate of cellular division with IH. Over the following decade IH continued to be used as a 
treatment for cancer. Patients reportedly tolerated the treatment well, but the therapy failed to 
slow the rate of cancer progression (Bernard & Buist, 2003). In the early 1940s, IH was first used 
for the purpose of improving neurological function in patients with head injury. Inducing a mild 
state of hypothermia during cardiac surgery was first introduced in 1950 and remains the 
recommended standard of practice for many cardiac surgical procedures because of its 
neuroprotective quality (Bernard & Buist, 2003). Animal trials began in the 1950s to examine the 
benefits of hypothermia as a therapeutic treatment and continued into the 1990s. Beginning in 
the 1990s, IH was specifically examined for its role in increasing central venous oxygen levels 
and decreasing arterial lactate concentrations in cases of head injury and witnessed cardiac arrest 
(McKean, 2009). Clinical trials validated the laboratory findings that IH reduced cerebral 
metabolism and improved neurological outcomes. The release of two landmark studies in 2002 
presented IH as the best practice to preserve neurological function in patients following cardiac 
arrest (Safer & Kochanek, 2002; The Hypothermia after Cardiac Arrest Study Group, 2002). The 
use of IH to counteract secondary brain injury as a result of trauma and stroke are currently being 
implemented in some of the larger hospitals in the United States. Induction of IH is also now 
being considered for use by paramedics prior to hospital admission in patients with witnessed 
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cardiac arrest. The benefits of pre-hospital hypothermia are currently under investigation. Initial 
results appear promising, but research in this field is limited. In spite of research in support of 
this therapy, guidelines for implementing IH are lacking. 
 
 
7 
 
CHAPTER TWO: Research Findings 
Indications for Treatment 
 Hypothermia continues to grow in use in contemporary medicine, encompassing a 
widening spectrum of medical conditions where ischemia is the common denominator. 
Considered a recommended therapy following witnessed cardiac arrest, IH is now being 
implemented in some cases of stroke, spinal cord injury, traumatic brain injury, hepatic 
encephalopathy, and bacterial meningitis with initial research initiatives showing favorable 
outcomes (Finkelstein & Alam, 2010; Bernard & Buist, 2002).  
Cardiac Arrest and Anoxic Brain Injury 
 Patients who are unresponsive after witnessed cardiac arrest are recommended for IH. 
Patients admitted to the hospital in cardiac arrest often sustain severe neurologic injury due to the 
loss of cerebral perfusion (Bernard & Buist, 2003). The American Heart Association (AHA) 
recommends IH for patients of cardiac arrest whose underlying rhythm is ventricular fibrillation, 
although IH may also be beneficial in cases of non-ventricular fibrillatory arrest (McKean, 
2009). Identification of appropriate cases for IH includes consideration of initiation and duration 
of resuscitation efforts.  
In one study, acceptable criteria for IH included cardiac arrest patients on whom 
resuscitation efforts were initiated within 15 minutes of arrest (Bernard & Buist, 2003). Oddo et 
al. (2006) conducted a retrospective study on the impact of IH on 109 patients who were 
survivors of out-of-hospital cardiac arrest. Heart rhythms for these patients were ventricular 
fibrillation, asystole, or pulseless electrical activity (PEA). Patients were cooled to 33°C using 
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external cooling methods. Hypothermia was maintained for 24 hours followed by passive 
rewarming. During hypothermia, patients were mechanically ventilated and received sedation, 
analgesia, and paralysis. Study results compared patient outcomes between those treated with IH 
and patients treated with standard resuscitation methods. Standard resuscitation methods 
included maintaining mean arterial blood pressure (MAP) between 75-80 mm Hg and 
maintaining PaCO2 between 36-40 mm Hg. Outcomes were measured using the Glasgow-
Pittsburg Cerebral Performance Categories (CPC), which measures patient functionality. Of the 
patients in the experimental group whose presenting rhythm was ventricular fibrillation (VF), 
55.8% had good outcomes (CPC 1-2) in contrast to 25.6% from the control group (p=0.004). 
Poor outcomes (CPC 3-5) were associated with patients from both groups whose presenting 
rhythm was either PEA or asystole. Results showed direct correlation between IH and improved 
functionality following cardiac arrest (Oddo, Schaller, Feihl, Ribordy, & Liaudet, 2006). 
Traumatic Head Injury 
 IH was considered an acceptable treatment for traumatic head injury in the 1950s but was 
abandoned with the development of intensive care units. Treatment for traumatic head injury is 
directed at minimizing secondary cerebral injury by promoting cerebral oxygenation. IH is now 
being reconsidered and reintroduced by some hospitals as a treatment modality to manage 
complications of traumatic head injury (Bernard & Buist, 2003). The premise for IH in traumatic 
head injury is the decrease in oxygen demands and reduction of ICP afforded by this therapy. 
Existing research shows IH to be non-therapeutic in traumatic head injury and is largely 
controversial, although further investigation is warranted (Bernard & Buist, 2003).  
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 A randomized study conducted by Clifton et al. (2001) examined the use of IH on 392 
patients admitted to the hospital with severe head injury. Patients in the hypothermia group 
(n=199) were cooled to 33°C for 48 hours. Although patients in the hypothermia group (n=199) 
experienced a reduction in intracranial pressure greater than their counterparts in the control 
group (n=193), there was no difference in functional outcomes between the two groups 6 months 
following treatment (Clifton et al., 2001). Limitations in methodology may have impacted 
patient outcomes in this study. Patients with hypoxia or hypotension following initial 
resuscitation efforts were excluded from this study and may have benefited from reduced oxygen 
demands and consumption afforded by IH. Furthermore, the mean time for initiating IH was 8 
hours following traumatic head injury. Lastly, rewarming was initiated after 48 hours of 
treatment regardless of intracranial pressure measurements, allowing patients with intracranial 
hypertension who may have benefitted from additional IH to be rewarmed (Clifton et al., 2004).    
Stroke 
 Although first line treatment for ischemic stroke is aimed at early thrombolytic therapy, 
treatment for stroke patients is largely supportive in nature. When a stroke occurs, a core of 
irreversibly dead tissue exists at the site of infarction. Surrounding the infarction is a region of 
hypoperfused tissue known as the ischemic penumbra. The focus of stroke management is on 
restoring perfusion to the area of ischemia, thereby minimizing the extent of neurological 
damage (Bernard & Buist, 2003). IH is an intervention that may be beneficial in this patient 
population. Increased body temperature is an adverse effect of stroke and is associated with 
adverse outcomes and increased mortality rates. Preclinical trials have shown improved 
outcomes in the use of IH in patients with ischemic stroke (Bernard & Buist, 2003). 
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 A prospective study of 390 stroke patients was conducted to see if laboratory findings 
that cerebral ischemia improved with hypothermia could be validated in humans following 
ischemic stroke. The study was conducted on patients who were admitted to the hospital within 6 
hours of stroke symptom onset and examined the correlation between body temperature on 
admission and the infarct size, mortality rates, and survivor outcomes. Patients presenting with 
hyperthermia had increased rates of mortality and poorer outcomes at discharge. Functional 
outcomes were measured using the Scandinavian Stroke Scale (SSS). Findings affirmed that 
body temperature was directly related to stroke severity (p<0.009), infarct size (p<0.0001), 
mortality (p<0.02), and survivor outcomes (p<0.002) (Reith et al., 1996). Although this study 
was conducted prior to clinical application of IH in stroke patients, it validated the 
neuroprotective nature of IH in this specific population. 
  A preliminary clinical trial conducted on 50 patients with ischemic stroke used IH to 
lower ICP and minimize secondary infarction. Hypothermia-induced complications were as 
follows: 70% experienced thrombocytopenia, 62% had bradycardia, and 48% developed 
pneumonia. Complications during rewarming occurred in 30% of those studied. In spite of these 
complications, outcomes found IH to effectively control ICP and reduce functional and 
neurological deficits. Patient outcomes were evaluated at 4 weeks and 3 months using the 
National Institutes of Health Stroke Scale (average score of 29 at 4 weeks) and the Rankin Scale 
(average score of 2.9 at 3 months) (Schwab et al., 2001). 
Hepatic Encephalopathy 
 IH for treatment of hepatic encephalopathy focuses on reducing increased ICP associated 
with acute liver failure. Animal studies have shown that IH reduced the levels of ammonia-
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induced cerebral edema (Bernard & Buist, 2003). A study conducted by Rose et al. (2000) 
examined the impact of hypothermia on rats with ammonia-related cerebral edema secondary to 
liver failure. Cooled to 35°C, the experimental group showed decreased ammonia levels in 
cerebrospinal fluid and lower levels of extracellular glutamate than the control group, providing 
positive support for the theory that IH is effective in reducing ammonia-induced cerebral edema 
(Rose et al., 2000).  
 Two research studies conducted by Jalan et al. (1999; 2001) evaluated the effects of IH in 
patients with hepatic encephalopathy. In the first study, patients were cooled to 32°-33°C for a 
mean time of 32 hours. In the second, patients were cooled to the same temperature range 24 
hours prior to surgery for liver transplantation and maintained between 32-33°C until the 
postoperative period. IH was effective in managing increased ICP for patients in acute liver 
failure awaiting liver transplants who did not respond to standard treatment with mannitol and 
ultrafiltration. Positive outcomes were a reduction in ICP by an average of 54 mm Hg, decreased 
arterial ammonia levels, and decreased cerebral uptake of ammonia. Neither study documented 
any long-term adverse effects of hypothermia (Jalan, Damink, Deutz, Lee, & Hayes, 1999; Jalan 
& Damink, 2001).  
Bacterial Meningitis 
 IH has the potential to lower ICP, blunt any hyperemic response in cerebral blood flow, 
and decrease leukocyte count in cerebral spinal fluid (CSF) (Bernard & Buist, 2003). Animal 
studies have been conducted to explore the possibility of using IH in the treatment of bacterial 
meningitis. Pneumococcal meningitis was introduced to rats that were then treated with IH to 
assess the impact of IH on cerebral blood flow and ICP. The study found that IH lowered 
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cerebral blood flow and ICP in addition to decreasing tumor necrosis factor and cerebrospinal 
fluid leukocyte count (Angstwurm et al., 2000). Clinical trials have not been started, but 
application of IH in this patient population may be considered (Bernard & Buist, 2003).  
Spinal Cord Injury 
 A limited number of animal studies analyzed the possibility of using IH to improve 
outcomes with spinal cord injury. While direct damage to the spinal cord is likely irreversible, IH 
may be useful in preventing secondary injury related to altered perfusion, ischemia, and 
inflammation (Finkelstein & Alam, 2010). Animal trials in the 1960s and 1970s looked for 
correlations between IH and improved outcomes with spinal cord injury. Results were 
inconclusive with only limited studies showing benefit of IH therapy. Animal studies on the use 
of IH for spinal cord injury resumed a decade ago as IH was becoming more widely used to treat 
cerebral inflammation and ischemia. Study results showed that IH provided a measure of 
cerebral protection, but improvement of functional outcomes was lacking (Inamasu, Nakamura, 
& Ichikizaki, 2003). Additional preclinical studies need to be completed before therapeutic 
benefits can be determined (Finkelstein & Alam, 2010). 
Exclusion Criteria 
 In a literature review, McKean (2009) concluded that IH is not recommended for patients 
with life-threatening arrhythmias or those who are pregnant due to the lack of available research 
among these patient populations (McKean, 2009). Primary coagulopathy was also a 
contraindication for this therapy because of the potential for IH to further impede coagulation 
(McKean, 2009). Immunosuppression and sepsis were also considered contraindications for IH 
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due to increased risk for infection. IH was not recommended for persons with cardiac arrest 
secondary to respiratory compromise, or for patients with a systolic blood pressure of less than 
90 mm Hg (McKean, 2009). Hypotension and decreased cardiac output have the potential to 
adversely affect cerebral perfusion pressure (CPP), which may be difficult to manage in patients 
presenting with hypotension (Huether & McCance, 2008). Similar exclusion criteria were listed 
in literature presented by Hoag Memorial Hospital Presbyterian. Exclusion criteria were 
subdivided into two groups: absolute and relative. Absolute exclusion criteria were listed as 
pregnancy, coma resulting from drug overdose, status epilepticus, and terminal illness. Relative 
exclusion criteria included preexisting coagulopathy, thrombocytopenia, preexisting 
hypotension, and bradycardia. Hoag Memorial established its exclusion criteria based on a 
review of functional outcomes of patients treated with hypothermia following cardiac arrest 
(Pyle, Pierson, Lepman, & Hewett, 2007). 
Methods for Inducing Hypothermia 
Noninvasive Cooling Measures 
 Cooling by conduction utilizes a cooling blanket that circulates chilled water. Cooling by 
convection uses fans to circulate cool air over the patient. These cooling methods generally 
produce slower reduction in core body temperature than invasive techniques. One study showed 
the use of cooling blankets to reduce body temperature by 1°C in a mean time of 178 minutes. 
Fans reduced core body temperature by a single degree in 142 minutes (Bernard & Buist, 2003). 
Additional methods of noninvasive cooling are alcohol baths, ice packs placed on the torso, groin 
and axillae, and immersion in ice water. Ice packs cool body temperature at an average rate of 
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0.9°C per hour. Immersion in ice water is effective in lowering body temperature but is difficult 
to implement in any hospital or pre-hospital setting (Bernard & Buist, 2003). 
 The above noninvasive methods of inducing hypothermia tend to be labor intensive for 
healthcare workers implementing the treatment and require close monitoring of the patient’s 
temperature which can be erratic and unpredictable. Nursing judgment plays a significant role in 
the care of patients receiving noninvasive cooling since treatment requires continuous adjustment 
based on the patient’s response to the intervention. Noninvasive cooling methods are associated 
with greater risk for accidental overcooling and excessively rapid rewarming. An additional 
concern is the prolonged time it may take to achieve target body temperature by surface cooling 
methods (McKean, 2009).  
 An exception to the aforementioned noninvasive cooling methods are external cooling 
devices such as the Arctic Sun. Advances in technology have led to the development of 
noninvasive cooling methods that regulate the rate at which body temperature is lowered and 
raised and provide continuous feedback on core body temperature. Arctic Sun uses adherent gel 
pads attached to the patient’s torso and lower extremities to circulate chilled fluids. Arctic Sun 
contains a temperature feedback-control mechanism that improves thermoregulation by allowing 
temperature to be raised or lowered on demand. An additional benefit is the ability to reach 
target core body temperature more rapidly than with other external cooling devices (Heard et al., 
2009).  
 A randomized control trial completed in 2009 compared the use of Arctic Sun to ice and 
cooling blankets for inducing hypothermia following cardiac arrest (Heard et al., 2009). The 
percentage of participants in the Arctic Sun group who reached target core body temperature 
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within four hours of induction was 71% in contrast with 50% for the control group (p = 0.12). 
Neurological function and survival rates were slightly higher in the Arctic Sun group at 46% 
compared with 38% in the control group (p = 0.6) (Heard et al., 2009). While cooling blankets 
and ice do effectively cool patients, improved technology, such as Arctic Sun, provide greater 
efficiency in cooling with the added benefit of precise temperature control (Heard et al., 2009).   
Invasive Cooling Measures 
 Rapid infusion of chilled IV fluids and intravascular cooling catheters are invasive 
methods of inducing hypothermia. Intravascular catheters inserted via a central vein into the vena 
cava circulate chilled fluid from an external refrigerated pump through a closed catheter. 
Preliminary research shows intravascular catheters to be an effective technique for cooling core 
body temperature. Risks associated with this cooling method include bleeding, deep vein 
thrombosis, vascular puncture, and infection, and must be weighed against therapeutic benefits 
(Bernard & Buist, 2003).  
 A pilot study by De Georgia et al. (2004) assessed the use of intravascular cooling 
catheters in patients following ischemic stroke. Eighteen participants were included in the study. 
Intravascular cooling was chosen because it facilitated quick access and rapid cooling. Target 
core body temperature of 33°C was attained within 2 hours of catheter placement for 14 of the 18 
participants, in contrast with the standard 4-6 hours required by other cooling methods. 
Hypothermia was successfully maintained for 24 hours. Occurrence of complications was 
comparable to those in the control group and patients remained hemodynamically stable for the 
duration of treatment. Participants who experienced complications had similar variables 
including advanced age and greater stroke severity. One exception was a patient who 
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experienced retroperitoneal hemorrhage. This patient was a poor candidate for intravascular 
cooling due to administration of antithrombolytics and anticoagulants prior to catheter insertion. 
Results of the study showed that hypothermia reduced the size of infarct growth, but functional 
outcomes were the same in both the experimental and control groups (De Georgia et al., 2004). 
Regional Cooling Measures 
 Partial body hypothermia uses a regional cooling device such as a cooling helmet to 
provide localized brain cooling. Theoretically, providing therapeutic benefits of cooling without 
subjecting the body to the systemic effects of whole body hypothermia could optimize treatment 
outcomes by minimizing the risk for complications. Research, however, is conflicting and use of 
cooling helmets needs to be further researched. Some studies have shown that cooling helmets 
are useful in providing regional hypothermia; however, after 24 hours of use, they begin to 
reduce core body temperature (Bernard & Buist, 2003; Finkelstein & Alam, 2010). An article by 
Kuffler (2010) supported the use of head cooling in combination with mild total body 
hypothermia to minimize the complications associated with systemic, moderate IH.  
Potential Adverse Effects of Induced Hypothermia 
Shivering 
Core body temperature is tightly regulated by the hypothalamus between 36.5°-37.5°C. 
Changes outside normothermic range initiate thermoregulatory responses within the 
hypothalamus. Hypothermia triggers the body’s compensatory mechanisms to increase heat 
production. One mechanism is increased muscle tone in the form of shivering, which causes the 
body to generate heat two to five times the normal rate (Mahmood & Zweifler, 2007). In the 
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induced hypothermic state, shivering potentiates an increase in metabolic demands and cellular 
oxygen consumption. This is most likely to occur during the induction and rewarming phases of 
IH (McKean, 2009). Increased metabolic rate and oxygen consumption are counterproductive 
during IH, and must be overcome to increase the efficacy of treatment (Mahmood & Zweifler, 
2007). 
Pharmacologic agents are used to suppress shivering and include paralytics and 
nonvolatile anesthetics. Propofol (Diprivan) is a benzodiazepine that impairs vasoconstriction 
and is useful as a sedative and anxiolytic for mechanically ventilated patients (Sole, Klein, & 
Moseley, 2009). Propofol is the medication of choice to prevent shivering in IH patients 
(Mahmood & Zweifler, 2007). Meperidine (Demerol) is an opioid used as an anesthesia adjunct 
and has also been shown to suppress shivering during IH (Deglin & Vallerand, 2009; Mahmood 
& Zweifler, 2007). Other medications used for patient sedation and comfort are fentanyl 
(Sublimaze) and midazolam (Versed) (Deglin & Vallerand, 2009). Neuromuscular blocking 
agents provide therapeutic paralysis and include atracurium (Tracrium) and succinylcholine. 
Prior to administering paralytics and sedatives, the patient must be intubated to maintain airway 
patency and placed on a ventilator until the use of sedation is suspended (Sole, Klein, & 
Moseley, 2009). Current research validates the suppression of shivering from the onset of IH 
through the duration of treatment until the body is rewarmed and returned to a normothermic 
state (McKean, 2009).  
Nursing assessment should include monitoring for signs of shivering such as increased 
respiratory rate and muscle tensing of chest or facial muscles. Other signs of shivering may 
include a reduction in venous oxygen saturation or a static tracing on the electrocardiogram 
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(ECG). Although it may be difficult to obtain due to peripheral vasoconstriction, a train of 4 
should be established on the patient and monitored throughout the sedation period (McKean, 
2009). Nursing assessment may be enhanced by the use of bispectral index monitoring to provide 
optimal sedation and reduce the risk of oversedation or excessive paralysis. 
Cardiovascular Changes 
 The body’s normal response to hypothermia is decreased heart rate, increased cardiac 
output, and peripheral vasoconstriction in an attempt to shunt blood to the vital organs and body 
core in an effort to conserve heat. Cardiovascular changes occur in two phases as body 
temperature lowers to a hypothermic state. During the induction phase heart rate is increased, 
thereby increasing cardiac output. Blood pressure also rises due to increased systemic vascular 
resistance. This compensatory mechanism allows greater volumes of warm blood to be circulated 
throughout the body to warm the tissues. As hypothermia persists and core body temperature 
lowers, bradycardia develops, afterload decreases, and cardiac oxygen demands are reduced 
(Polderman, 2004). Hypotension and dysrhythmias are two adverse cardiovascular effects seen 
during this phase of IH. The use of sedatives or paralytic agents compounds the body’s natural 
response causing bradycardia and increased systemic vascular resistance (Bernard & Buist, 
2003).  
To compensate for increased arterial pressure, the kidneys respond with diuresis in an 
effort to lower blood pressure. Within hours, the body may lose large amounts of water (Guyton, 
1991). Ensuing hypotension and decreased cardiac output have the potential to adversely affect 
CPP. If pressure in the vasculature of the brain is inadequate, oxygenation of cerebral cells will 
be insufficient (Huether & McCance, 2008). An injured brain is highly sensitive to changes in 
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blood volume and pressure and cannot survive long without adequate oxygenation (Finkelstein & 
Alam, 2010). Inadequate CPP leads to cerebral ischemia within three minutes and cerebral 
infarction in five minutes (Sole, Klein, & Moseley, 2009).  
Hemodynamic monitoring is critical in these patients to assess fluid volume status and 
maintain adequate cerebral perfusion. Invasive hemodynamic monitoring devices include arterial 
lines, central venous catheters, and pulmonary artery catheters. Complications associated with 
these devices are infection, bleeding, pneumothorax or hemothorax, thrombosis, cardiac 
dysrhythmias, and pericardial tamponade. Proper management of arterial catheters includes 
zeroing the transducer at the start of every shift, when the patient is repositioned or moved, and if 
there is a significant change in patient status (Sole, Klein, & Moseley, 2009). 
Fluid replacement is important to ensure adequate fluid volume and cerebral perfusion. 
The fluid of choice during hypothermia is 0.9% normal saline. Normal saline helps maintain 
optimal CPP and mean arterial pressure (MAP) (Sole, Klein, & Moseley, 2009). 
Monitoring vital signs provides the nurse with critical information regarding the patient’s 
response to hypothermia. Continuous blood pressure monitoring is essential in IH patients. 
Arterial catheters provide accurate measurement of systemic blood pressure and are the modality 
of choice for patients undergoing IH (Sole, Klein, & Moseley, 2009). Cerebral oxygenation 
monitoring is another valuable tool that allows the healthcare team to assess cerebral perfusion 
by the placement of a jugular venous bulb via the internal jugular vein. The monitor measures 
the level of oxygen saturation of the blood as it leaves the brain (Sole, Klein, & Moseley, 2009). 
Research on appropriate CPP levels is conflicting. During induced hypothermia one study 
suggested maintaining a CPP of 60 mm Hg (Finkelstein & Alam, 2010). According to Huether 
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and McCance (2008), a CPP of more than 70 mm Hg is recommended. Normal adult CPP is 
between 60-100 mm Hg. Decreased MAP or increased ICP causes CPP to be lowered. During 
hypothermia, a lower CPP may be acceptable because of decreased metabolic rate (Sole, Klein, 
& Moseley, 2009).   
Hypothermic patients are also at risk for developing dysrhythmias. These can occur in 
response to decreased coronary perfusion and increased myocardial irritability. Without oxygen, 
the myocardium becomes fatigued and escape mechanisms replace normal conduction pathways. 
Although the heart can withstand episodes of ischemia for longer periods than the brain before 
infarct occurs, adequate perfusion is essential for proper function (Sole, Klein, & Moseley, 
2009). 
 Hypokalemia is a common occurrence during IH due to cellular shifts of fluids and 
electrolytes. Potassium is essential for cellular metabolism and plays an essential role in 
neuromuscular function. Hypokalemia impacts resting membrane potential and specifically 
impacts the electrical conductivity of the myocardium by reducing cellular excitability. ECG 
changes associated with hypokalemia include flattened T waves, emergence of U waves, and 
peaked P waves (Lewis, Heitkemper, Dirksen, O’Brien, & Bucher, 2007). Dysrhythmias may 
develop at any point during IH, but are most likely to occur during the induction and rewarming 
phases (McKean, 2009). 
Research findings showed the risk for dysrhythmias increased when body temperature 
fell below 30°C (McKean, 2009; Polderman, 2004). The most common ECG changes seen in 
patients with temperatures below 32°C were first-degree heart block and prolonged QT segment 
(Finkelstein & Alam, 2010). Tachydysrhythmias, most commonly atrial fibrillation, were 
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associated with temperatures between 30°-33°C. In deep, hypothermic states (less than 28°C), 
ventricular dysrhythmias were problematic (Finkelstein & Alam, 2010).  
Nurses managing the care of IH patients should be aware of the risk for hypothermia-
induced dysrhythmias and monitor for changes in heart rate and rhythm. Early recognition of 
ECG changes followed by early intervention reduces strain on the heart and helps reduce risk for 
more serious dysrhythmias (Sole, Klein, & Moseley, 2009). Treatment of dysrhythmias involves 
standard medical interventions, although dysrhythmias may be more difficult to treat due to the 
impact cold temperatures have on the myocardium. Awareness of alterations in drug metabolism 
is an important factor in treating dysrhythmias (Finkelstein & Alam, 2010; McKean, 2009). 
Hypothermic patients may require lower or less frequent doses of antiarrhythmic medications 
due to slower drug metabolism (McKean, 2009).   
Coagulopathy 
 Hypothermia depletes clotting factors and clotting proteins and activates both intrinsic 
and extrinsic pathways causing the release of procoagulants. Consumption of clotting factors in 
the microcirculation increases systemic risk for bleeding. Uncontrolled clot formation throughout 
the microvasculature also increases the risk of organ ischemia and damage (Sole, Klein, & 
Moseley, 2009). Methods for assessing coagulation include platelet count, fibrinogen level, 
fibrin degradation products (FDPs), international normalized ratio (INR), prothrombin time (PT), 
and activated partial thromboplastin time (aPTT) (Sole, Klein, & Moseley, 2009). 
 The studies under review used PT and aPTT as the methods of choice for assessing risk 
for bleeding in hypothermic patients. Preclinical trials showed varying impact of IH on bleeding 
tendencies. A meta-analysis revealed only slight increase in PT between the hypothermic and 
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normothermic groups by 0.02 seconds (p=0.7) (Harris, Colford, Good, & Matz, 2002). One of 
four research studies conducted by a traumatic brain injury group showed an increased PT during 
IH (Finkelstein & Alam, 2010). According to Polderman (2004), IH was not associated with 
increased intracranial bleeding in clinical trials for patients with stroke, subarachnoid 
hemorrhage, or traumatic brain injury. Two human trials showed no increased risk for bleeding 
during mild to moderate hypothermia (28°-36°C) (McKean, 2009, Clifton et al., 2001). The risk 
for bleeding increased when body temperature was decreased to below 28°C (Finkelstein & 
Alam, 2010).  
Assessment for signs and symptoms of coagulopathy should include monitoring for 
changes such as cyanosis of the fingers, toes, and nose, and delayed capillary refill. Oliguria, a 
possible sign of coagulopathy, may be difficult to monitor in patients who are vasoconstricted 
due to hypothermia. Patients should also be closely monitored for signs of bleeding such as 
gingival bleeding, petechiae, echymosis, oozing at venipuncture sites, and stool positive for 
occult blood (Sole, Klein, & Moseley, 2009). 
Infection 
 Hypothermia inhibits proinflammatory responses by decreasing the number of circulating 
leukocytes, suppressing phagocytosis, and decreasing the synthesis of proinflammatory 
cytokines (Polderman, 2004). Hypothermia places patients at increased risk for developing 
infection and sepsis. Meningitis, pneumonia, and wound infections or prolonged wound healing 
are the most common infections associated with induced hypothermia (Finkelstein & Alam, 
2010). Immunosuppression, in addition to intubation and mechanical ventilation, place ventilated 
patients at greater risk for developing ventilator-associated pneumonia (VAP) (Sole, Klein, & 
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Moseley, 2009). Hypothermia impairs ciliary function of the upper airways, thus inhibiting one 
of the body’s natural defense mechanisms (McKean, 2009). Wound infections associated with IH 
are attributed to diminished leukocyte function and hypoperfusion resulting from hypothermia-
induced vasoconstriction (Polderman, 2004). 
  Infection, specifically pneumonia, occurred in higher numbers when the hypothermic 
period lasted greater than 48 hours (Polderman, 2004).  Incidence of hypothermia-related 
pneumonia was one of the documented complications found in 11 trials (n=559). Patients in 
hypothermic groups had a moderately higher risk for acquiring pneumonia than the control 
groups, but in these studies the increase was not shown to be significant (confidence interval 
0.95-1.91) (Sydenham, Roberts, & Alderson, 2009). Infections that did occur responded well to 
treatment once the patients were rewarmed (Finkelstein & Alam, 2010). 
Strategies to reduce the risk for infection during IH include maintaining the head of the 
patient’s bed between 30°- 45°C if not contraindicated by patient condition. Raising the head of 
the bed helps reduce risk for aspiration and prevent gastric reflux. Suctioning of mechanically 
ventilated patients and providing oral hygiene are important aspects of nursing care to reduce the 
risk for pneumonia (Sole, Klein, & Moseley, 2009). Laboratory indicators for infection are white 
blood cell (WBC) count with differential and blood cultures and should be routinely monitored 
throughout the hypothermic period (Greer, 2005).  Skin care and frequent turning help maintain 
skin integrity (McKean, 2009). Additional protective measures include antibiotic prophylaxis 
and decontamination of the gastrointestinal tract (Polderman, 2004). IH masks elevation in body 
temperature associated with infection, placing greater responsibility on nurses to use proactive 
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measures to prevent infection and astute assessment to detect the earliest signs of infection 
(McKean, 2009).  
Fluid and Electrolyte Imbalances 
 Induction of hypothermia causes a significant shift of electrolytes from the extracellular 
fluid (ECF) to the intracellular fluid (ICF) causing serum levels of potassium to drop (Huether & 
McCance, 2008). In addition to the intracellular shift, decreased renal reabsorption of solutes 
leads to increased secretion of electrolytes (Bernard & Buist, 2003). A reduction in calcium, 
potassium, sodium, magnesium, and phosphate are all possible findings due to shifts in 
electrolytes and urinary diuresis (Finkelstein & Alam, 2010). One of the most concerning 
changes is a shift of potassium into the cells resulting in extracellular hypokalemia. Potassium 
plays a vital role in electrical impulse conductivity, and has specific impact on the myocardium. 
Cardiac dysrhythmias, including bradycardia and ECG changes such as a depressed ST segment, 
flattened T wave, and prolonged QT segment, are findings associated with hypokalemia (Sole, 
Klein, & Moseley, 2009). Hypomagnesemia is a finding associated with poor patient outcomes 
when experienced in conjunction with neurological injury and may be seen with hypothermia 
(Finkelstein & Alam, 2010).  
 Electrolyte monitoring is essential in patients undergoing IH. ECG readings should be 
closely monitored for changes consistent with hypokalemia. Replacement of potassium levels 
requires diligent and frequent monitoring as levels can drop dramatically and rapidly throughout 
the hypothermic phase. There are two options for replacing potassium during hypothermia. The 
first is to maintain normal serum potassium levels. The second is to replace measured losses of 
potassium. In one research study, patients whose potassium was maintained at a normal serum 
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level during hypothermia, developed hyperkalemia during the rewarming phase and more 
frequently experienced dysrhythmias. Patients whose potassium was replaced according to 
measured losses stayed within normal levels during rewarming and did not experience 
dysrhythmias (Koht, Cane, & Cerullo, 1983). While it is commonly thought that electrolyte 
levels should be maintained in the high range of normal, it may be wise to replace only measured 
losses in the case of potassium (Finkelstein & Alam, 2010).  
Magnesium plays an important role in neuromuscular excitability. Effects of 
hypomagnesemia include hyperreflexia, muscle cramps, convulsions, tachycardia, and 
hypotension (Huether & McCance, 2008). Magnesium replacement during IH may benefit the 
patient by preventing vasospasm and aid in regulating the body’s transition during reperfusion. 
According to Finkelstein and Alam (2010), hypomagnesemia during induced hypothermia was 
associated with increased mortality and poor outcomes in patients with neurological injury. In 
cases of traumatic brain injury, supplementing magnesium resulted in improved patient outcomes 
(Finkelstein & Alam, 2010). 
In addition to replacing electrolytes, slow infusions of hypertonic saline may be 
administered if electrolyte levels are critically low and electrolyte levels are not improving 
sufficiently with replacement therapy (Sole, Klein, & Moseley, 2009).  
Adverse Metabolic Effects 
 During periods of hypothermia, the body functions in a hypometabolic state. Metabolic 
rate decreases 5%-7% for each degree Celsius that body temperature is lowered (Polderman, 
2004). Decreased metabolism impacts cellular uptake of insulin by increasing insulin resistance 
and decreasing pancreatic secretion of insulin. Both of these factors place the body at risk for 
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developing hyperglycemia (Finkelstein & Alam, 2010). Hyperglycemia increases susceptibility 
to infection in vulnerable patients whose immune function is suppressed (Polderman, 2004).  
There are no clear guidelines for the management of hyperglycemia during IH. Two 
studies of patients with traumatic brain injury linked tight glucose control to improved patient 
outcomes. Higher amounts of insulin were required during the induction phase of hypothermia to 
maintain blood glucose within therapeutic range (Polderman, 2004). A clinical trial and meta-
analysis, however, showed that tight glucose control involving frequent insulin administration 
appeared to adversely impact patients and possibly contributed to increased mortality 
(Finkelstein & Alam, 2010). A concern with aggressive administration of insulin during the 
hypothermic phase is rebound hypoglycemia during rewarming (Polderman & Ingeborg, 2009). 
A further consideration for glycemic control is the impact of hyperglycemia on blood viscosity. 
Hyperglycemia increases blood viscosity, which decreases perfusion (Sole, Klein, & Mosely, 
2009). Critical care nurses need to diligently assess blood glucose levels in these patients and 
communicate with physicians to provide safe management of this potential adverse effect. 
Research studies showed hyperglycemia to be the single greatest metabolic abnormality 
associated with IH (Polderman, 2004; Finkelstein & Alam, 2010). Additional metabolic risks do 
exist, however, including pancreatitis and impaired liver function that result in elevated liver 
enzymes and amylase levels (Finkelstein & Alam, 2010). Hypothermia can lead to acidosis due 
to increased levels of fatty acids, ketones, and lactate. This places the bowel at increased risk for 
ulcer formation. Bowel ischemia due to hypoperfusion reduces gastrointestinal (GI) motility and 
increases the risk of ileus and ulcer formation (Polderman, 2004). ICU protocols for GI antibiotic 
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prophylaxis should be closely adhered to in IH patients (Finkelstein & Alam, 2010; Oddo et al., 
2006).    
Reduced Drug Metabolism 
 The effects of hypothermia significantly impact pharmacokinetics and 
pharmacodynamics. Enzymes necessary in the metabolism of most medications are highly 
sensitive to changes in temperature. Drug clearance during hypothermia is decreased causing 
plasma drug levels to be higher for prolonged periods of time, requiring lower doses of 
medication to achieve the desired effects (Finkelstein & Alam, 2010; Polderman, 2004). 
Consequently, standard dosing schedules may lead to plasma drug accumulation and toxicity. 
Critical care nurses need to be cognizant of this fact and monitor for adverse effects of drug 
toxicity such as respiratory depression and changes in heart rate or blood pressure. 
Communication with the healthcare team, specifically physicians and pharmacists, is imperative 
as drug doses and frequency of medication administration may need to be adjusted to prevent 
toxicity (Lewis et al., 2007). Medications of specific concern for hypothermic patients are 
opiates, sedatives, vasoactive drugs, nitrates, beta blockers, and neuromuscular blocking agents 
(Polderman & Ingeborg, 2009).  
Risks During Rewarming 
 Reperfusion injuries are exacerbated during the rewarming phase of IH. The brain’s shift 
to anaerobic metabolism during initial loss of perfusion causes toxins to accumulate in the brain 
(Zeitzer, 2005). Free radicals, cytokines, catecholamines, and nitric oxide are released when 
reperfusion occurs (McKean, 2009). The presence of these chemicals furthers the injury when 
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the body transitions from a hypothermic to normothermic state. Electrolyte imbalances, 
specifically hyperkalemia, may occur during the rewarming phase as electrolytes shift from 
intracellular spaces to the extracellular. Cellular uptake of insulin also increases as the body 
returns to normothermia placing the patient at risk for hypoglycemia (Polderman & Ingeborg, 
2009). Signs of medication toxicity should be closely assessed during the rewarming phase when 
the body’s metabolism increases, thereby enhancing the uptake of pharmacotherapies 
(Finkelstein & Alam, 2010). Other concerns include rebound hyperthermia and hypotension. 
Rebound hyperthermia may increase cerebral edema and potentiates the risk for mitochondrial 
damage and cell death, thereby reversing the therapeutic benefits of IH (McKean, 2009). The 
rate at which body temperature is returned to a normothermic state must be monitored closely to 
reduce the risk of recurring cerebral edema and increased intracranial pressure (McKean, 2009).  
 To prevent adverse effects of rewarming, studies suggest gradually increasing body 
temperature by 0.5°-1.0°C per hour (McKean, 2009). Patient monitoring during the rewarming 
phase should include assessment for electrolyte imbalances and dysrhythmias. Blood glucose 
levels need to be monitored for hypoglycemia. Blood gasses should be assessed and oxygen 
levels titrated to prevent oxidative stress from occurring as excessive oxygen is detrimental in 
cases of post-ischemic neurological dysfunction. Vital signs should be continuously monitored 
for changes in blood pressure, heart rate, and temperature. Shivering should continue to be 
suppressed until normothermia is reestablished (McKean, 2009). Nurses should watch for ECG 
changes such as bradycardia, first-degree heart block, and prolonged QT segment (Finkelstein & 
Alam, 2010). 
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Induced Hypothermia in the Prehospital Setting 
 Early implementation of IH has been shown to be effective in improving neurological 
outcomes and minimizing secondary injury from ischemia. This finding has led to initiation of 
this therapy by emergency medical service (EMS) personnel during prehospital transport 
(Cabanas, Brice, Maio, Myers, & Hinchey, 2011). Numerous variables exist in the field, each 
with the potential to impact effectiveness of IH delivery and management. Transport time may 
range from less than ten minutes in a well-serviced city to more than an hour in rural settings. 
EMS personnel possess a broad range of certification and experience. Some operate as 
volunteers, others work full-time. Certification includes basic EMTs, paramedics, and in some 
states, intermediate level EMTs. Equipment and protocols vary between providers and areas of 
service. In order to analyze the benefits of IH, the risks of initiating this therapy in the 
prehospital setting must be considered.  
 As outlined in this literature review, there are a number of possible adverse effects 
associated with IH. Effectiveness of therapy is dependent on proper management of therapy-
induced complications. In the field, paramedics do not have access to resources and equipment 
necessary for monitoring these complications. A question to consider is could potential harm be 
done by initiating this therapy in the field where there are limitations to what can be monitored? 
One variable that comes into play is the duration of patient transport. During a short transport 
time (<15-30 min.) it would be unlikely for body temperature to be lowered to the point where 
complications would present a problem. On the other hand, a longer transport time (>30 min.) 
may place the patient at risk for developing complications that could not be monitored until 
hospital arrival. This raises a further question as to how EMS personnel should best prioritize 
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their time. Performing lifesaving interventions, such as securing an airway, stopping 
hemorrhage, immobilizing the C-spine or injured extremities, placing one or more IVs, obtaining 
vital signs, and possibly ventilating a patient or performing CPR require full involvement by 
paramedics and EMTs making it difficult to initiate other interventions such as IH.  
 The underlying question that needs to be determined is do the benefits of IH outweigh the 
risks? Does initiation of IH in the field contribute to positive neurological outcomes, or would 
the patient be better served by providing a speedy transport with preparatory communication to 
emergency department staff to enable early intervention in the hospital where the patient can be 
adequately monitored and assessed for complications? In order to answer these questions, further 
research needs to be conducted on the use of IH in the prehospital setting (Cabanas, Brice, Maio, 
Myers, & Hinchey, 2011). 
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CHAPTER THREE: Conclusion 
Implementation of Induced Hypothermia 
Plan of Care  
 IH occurs in three phases: induction, hypothermic, and rewarming. Before the induction 
phase is initiated, however, several factors should be determined. Appropriate patients should be 
identified based on guiding criteria. IH may be beneficial for patients following cardiac arrest, 
traumatic head injury, stroke, hepatic encephalopathy, bacterial meningitis, spinal cord injury, 
and neonatal encephalopathy. IH is not recommended in patients with life-threatening 
arrhythmias or those who are pregnant. Preexisting coagulopathy, immunosuppression, or sepsis 
are also contraindications for IH. Use of IH with a systolic blood pressure of less than 90 mm Hg 
or a history of recent surgery may place the patient at increased risk for complications and should 
be avoided. (McKean, 2009). 
 A second consideration is unit staffing and resources. Physiological status may change 
dramatically and rapidly during IH. A one-to-one nurse to patient ratio may be required to ensure 
patient safety and should be considered when making patient assignments.  
 Better patient outcomes are associated with early initiation of IH. Studies concur that 
induction of hypothermia should be implemented within 2-5 hours of anoxic brain injury or 
cardiac arrest (Oddo et al., 2006). Studies currently suggest a target body temperature of 32°-
34°C for a period of 24-48 hours (McKean, 2009). If IH is rapidly initiated, a period of 12 hours 
may be sufficient to produce therapeutic results. The rate at which body temperature is lowered 
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varies by cooling method. The time it should take to reach target temperature is recommended 
between 6-8 hours (Greer, 2005).   
 Vigilant nursing assessment is critical since patient status can change rapidly during the 
induction phase. Nurses should monitor for signs of shivering such as increased respiratory rate 
and muscle tensing of chest or facial muscles. Other signs of shivering may include a reduction 
in venous oxygen saturation and a static tracing on the ECG (Mahmood & Zweifler, 2007). 
Endotracheal intubation and mechanical ventilation may need to be established, requiring 
administration of opiates, paralytics, and neuromuscular blockers for providing patient comfort 
and enhancing therapeutic benefits (Mahmood & Zweifler, 2007). Bispectral index monitoring 
helps ensure optimal sedation and reduces the risk of oversedation.  
 During the induction phase vital signs should be closely monitored. Arterial lines 
facilitate continuous blood pressure monitoring. A systolic blood pressure greater that 90 mm Hg 
and mean arterial pressure (MAP) of greater than 80 mm Hg is desirable during IH (Greer, 
2005). Temperature monitoring may be obtained via pulmonary artery temperature probes or 
bladder temperature probes. ECG monitoring with attention toward bradycardia should be 
performed. A secondary temperature monitoring device may be advised in patients with bladder 
probes, since the reading of core body temperature is dependent on adequate urine output (Greer, 
2005).     
 Measures should be taken early to reduce patients’ risk for infection. If tolerated, the head 
of the patient’s bed should be elevated between 30°-45°. Suctioning secretions and providing 
oral hygiene are important aspects of nursing care to reduce the risk for pneumonia (Sole, Klein, 
& Moseley, 2009). White blood cell (WBC) count should be monitored. Skin care and frequent 
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turning help maintain skin integrity (McKean, 2009). If surface cooling methods are used, skin 
should be assessed every 2-6 hours for thermal injury (Bessman, Talavera, Setnik, Halamka, & 
Alder, 2010). Additional protective measures include antibiotic prophylaxis and antibiotic 
decontamination of the gastrointestinal tract (Polderman, 2004). 
 Fluid and electrolyte shifts begin during the induction phase. Hemodynamic monitoring 
and fluid replacement should be established at the beginning of treatment. Chemistry panels, 
CBC, and blood glucose levels should be obtained at 0, 12, and 24 hours. Blood cultures and 
ABG measurements are also recommended at 12 hour intervals (Greer, 2005).  
 Ongoing assessment should continue during the hypothermic period. During the 
hypothermic period each of the above functions requires close assessment. In addition to the 
assessments performed during the induction phase, timely monitoring and replacement of 
electrolytes are essential to prevent further complications. Potassium levels are of specific 
concern and need to be frequently assessed (Finkelstein & Alam, 2010). Medication 
administration for hypothermic patients may require lower than normal doses due to 
hypometabolism. Standard dosing schedules may lead to plasma drug accumulation and toxicity. 
Critical care nurses need to be cognizant of this potential effect and monitor for adverse effects 
of drug toxicity such as respirator depression and changes in heart rate or blood pressure (Lewis 
et al., 2007). 
 The rewarming phase may be passive or controlled. Passive rewarming involves the 
removal of cooling devices such as blankets or ice packs. Controlled rewarming is achieved by 
programming a cooling device such as the Arctic Sun or Cool Guard to the desired warming rate. 
For either method, the recommended rate of warming is 0.3°-1.0°C every hour until core body 
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temperature returns to 36°C. In general, normothermia should be achieved within 6-8 hours 
(Bessman et al., 2010).  
 During rewarming, the risk increases for rebound hyperkalemia, hyperthermia, 
hyperglycemia, and hypotension (McKean, 2009; Polderman & Ingeborg, 2009). Rewarming 
may be the most critical phase of IH as therapeutic effects may be reversed if complications and 
patient condition are poorly managed (Greer, 2005). The use of sedation and paralytics should 
continue until the patient achieves target, normothermic core body temperature. Medication 
doses may need to be adjusted as metabolism increases (Polderman & Ingeborg, 2009).    
Nursing Education and Research 
 Efficacy of treatment is largely dependent on early implementation of IH in patients 
meeting criteria for treatment. Nurses should be trained in identification of patients who may 
benefit from IH to promote early intervention. The variety of complications associated with IH 
requires proficiency in nursing care. Continuing education on methods for inducing hypothermia 
and the associated interventions that may be required to maintain patient stability can play a vital 
role in preparing nurses to manage patient care.  
 Additional research needs to be conducted to assess therapeutic benefits in populations 
where clinical trials are lacking, including head trauma, stroke, and spinal cord injury. Specific 
focus on management of complications should be addressed to promote development of 
recommendations for best practice. Rather than focusing on complications in general, it may be 
beneficial to conduct research studies addressing individual complications.  
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Summary 
 Hypothermia is documented to improve outcomes following anoxic brain injury, cardiac 
arrest, and stroke. As exploration in this field advances, IH is being considered to treat specific 
cases of traumatic head injury, bacterial meningitis, spinal cord injury, and hepatic 
encephalopathy. Animal studies are well-documented and show promising results. Human 
clinical trials, however, are limited and small in number with variable quality. Results of clinical 
trials show varying support for IH, and further research needs to be conducted to validate these 
findings. Studies to date show correlations between IH and physiological complications. As 
future studies are performed, medical personnel need to be informed of these adverse effects, so 
care is properly managed and therapeutic benefits are maximized.    
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APPENDIX: Table of Evidence 
Author / Year 
/ Title 
Study / 
Purpose 
Population 
Studied 
Complications 
Evaluated 
Results / 
Findings 
Conclusion / 
Implications  
Bernard & 
Buist, 2003 
 
Induced 
hypothermia in 
critical care 
medicine: A 
review 
Review IH as 
a treatment 
option for 
patients with 
neurologic 
disorders 
Anoxic brain 
injury 
following  
cardiac arrest, 
traumatic head 
injury, stroke, 
hepatic enceph-
alopathy, 
encephalitis, 
bacterial 
meningitis, 
ARDS, HF, 
and 
postoperative 
tachycardia 
CNS, acid-
base balance, 
electrolytes, 
and cardio-
vascular, 
respiratory, 
renal, GI, and 
hematologic 
systems 
Improved 
outcomes in two 
trials in patients 
with anoxic 
brain injury 
following 
cardiac arrest 
 
Variable results 
in patients with 
severe head 
injury 
 
Promising 
results in 
preliminary 
clinical trials of 
the use of IH 
with stroke, 
neurologic 
infection, and 
hepatic 
encephalopathy 
ICU patients 
meeting 
specific 
criteria should 
be considered 
for IH. Critical 
care 
physicians 
should be 
knowled-
geable in 
terms of 
physiologic 
effects of IH, 
methods of 
inducing IH, 
and potential 
complications.  
Clifton et al., 
2001 
 
Lack of effect 
of induction of 
hypothothermia 
after acute 
brain injury  
Compare 
outcomes in 
patients 
treated with 
IH and those 
who received 
standard 
treatment 
Comatose 
following 
closed head 
injury 
Fluid and 
electrolyte 
balance, lab 
value 
alterations, and 
hypotension 
Comparable 
outcomes and 
mortality rates 
between  to 
those  receiving 
IH and those 
treated with 
standard 
interventions 
Results were 
inconclusive. 
 
IH is not 
effective in 
improving 
outcomes in 
patients with 
severe brain 
injury. 
Finkelstein & 
Alam, 2010 
 
Induced 
hypothermia 
for trauma 
Discuss 
potential 
benefits and 
complications 
of IH in the 
trauma 
population, 
including 
penetrating 
trauma with 
Trauma with or 
without cardiac 
arrest, 
traumatic brain 
injury, spinal 
cord injury, 
and blunt 
trauma 
Increased 
infections, 
coagulopathy, 
hemodynamic 
effects, 
dysrhythmias, 
alterations in 
drug 
metabolism, 
and fluid, 
Uniform efficacy 
seen in 
preclinical trials 
with penetrating 
trauma with 
cardiac arrest, 
delaying cardiac 
arrest in trauma 
patients who are 
hypotensive, and 
Further study 
needed in SCI 
and blunt 
trauma; IH 
beneficial with 
other types of 
trauma, 
specifically 
penetrating 
trauma with 
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Author / Year 
/ Title 
Study / 
Purpose 
Population 
Studied 
Complications 
Evaluated 
Results / 
Findings 
Conclusion / 
Implications  
cardiac arrest; 
evaluate the 
role of IH in 
delaying 
cardiac arrest 
in 
hypotensive 
patients with 
penetrating 
trauma, and 
traumatic 
brain injury  
electrolyte, and 
metabolic 
disturbances 
traumatic brain 
injury 
 
Conflicting 
results between 
preclinical and 
clinical trials in 
traumatic brain 
injury patients 
cardiac arrest 
Kuffler, 2010 
 
Combinatorial 
techniques for 
enhancing 
neuroprotection  
Neuro-
protection 
provided by 
hypothermia  
 
Combining 
IH with other 
therapies and 
treatments 
Variety of 
neuronal 
insults 
Treatment of 
complications 
with neuro-
trophins, anti-
inflammatory 
agents, 
immune-
therapy, and 
alkalinization 
Survival rates 
and neurologic 
outcomes are 
significantly 
improved by 
whole body 
hypothermia 
Effective 
neuro-
protection 
possible when 
multiple 
treatments are 
implemented 
simul-
taneously. 
McKean, 2009 
 
Induced 
moderate 
hypothermia 
after cardiac 
arrest 
Overview of 
the patho-
physiology of 
cerebral 
ischemia and 
physiologic 
changes 
associated 
with IH. 
 
Overview of 
the history 
and 
research of IH 
following 
cardiac arrest. 
 
Nursing 
management 
considerations 
for patients 
with IH and 
consideration 
of IH protocol 
development. 
Inclusion 
criteria: 
Comatose 
following 
cardiac arrest 
 
Exclusion 
criteria: 
Patients with 
life-
threatenting 
arrhythmias, 
primary 
coagulopathy, 
pregnancy, and 
sepsis 
Prevention of 
shivering, VS 
monitoring, 
skin care 
issues, fluid 
and electrolyte 
imbalances, 
lab value 
monitoring, 
prevention of 
infection, and 
rewarming 
55% of patients 
with IH had 
favorable 
outcomes 
IH is 
beneficial 
following 
cardiac arrest, 
but 
implement-
tation has been 
slow. 
 
Additional 
protocols 
including 
detailed 
instructions 
need to be 
developed to 
encourage 
consistent and 
safe 
implement-
tation of IH. 
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Author / Year 
/ Title 
Study / 
Purpose 
Population 
Studied 
Complications 
Evaluated 
Results / 
Findings 
Conclusion / 
Implications  
Oddo, Schaller, 
Feihl, Ribordy, 
& Liaudet, 
2006 
 
From evidence 
to clinical 
practice: 
Effective 
implementation 
of therapeutic 
hypothermia to 
improve patient 
outcome after 
cardiac arrest 
Evaluate the 
use of IH in 
the ICU and 
whether IH 
improves 
outcomes of 
all comatose 
patients with 
cardiac arrest 
Comatose  
following out-
of-hospital 
cardiac arrest 
 IH had a positive 
impact on the 
outcome of 
patients in 
ventricular 
fibrillation and 
shock.  
 
Poor outcomes 
in patients with 
nonventricular 
dysrhythmias 
IH can be 
successfully 
implemented 
in the ICU and 
is beneficial to 
patients in 
cardiac arrest 
and shock. 
Polderman, 
2004 
 
Application of 
therapeutic 
hypothermia in 
the intensive 
care unit 
Evaluate the 
benefits and 
risks of IH 
Variety of 
neurological 
injuries 
Cardiovascular 
and 
hemodynamic 
effects, 
coagulo-
pathies, 
infection, 
hypovolemia, 
fluid and 
electrolyte 
imbalances, 
other 
metabolic 
effects, 
shivering, drug 
metabolism 
IH useful  in 
preventing or 
limiting damage 
to an injured 
brain or spinal 
cord 
Successful 
application of 
IH requires 
vigilant care 
and team 
effort. 
Sydenham, 
Roberts & 
Alderson, 2009 
 
Hypothermia 
for traumatic 
head injury 
Determine if 
the use of IH 
is beneficial 
in reducing 
the risk of 
death or 
severe 
disability in 
head trauma 
patients.  
 
Determine if 
IH places 
patients at 
risk for 
Closed 
traumatic head 
injury 
Pneumonia, 
unfavorable 
outcomes 
including 
vegetative 
state and 
severe 
disability 
Results were not 
statistically 
significant. 
No evidence 
that IH is 
beneficial in 
cases of head 
injury.  
 
IH may help 
reduce the 
occurrence of 
death, but 
significant 
benefit was 
only found in 
low quality 
trials. 
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Author / Year 
/ Title 
Study / 
Purpose 
Population 
Studied 
Complications 
Evaluated 
Results / 
Findings 
Conclusion / 
Implications  
pneumonia. 
 
Estimate the 
effects of IH 
on mortality 
and long-term 
functional 
outcomes in 
patients with 
traumatic 
head injury 
 
Determine if 
IH reduces 
the number of 
patients at the 
follow-up 
period who 
experienced 
unfavorable 
outcomes or 
death 
 
High quality 
trials found no 
decreased risk 
of death with 
IH  
Zeitzer, 2005 
 
Inducing 
hypothermia to 
decrease 
neurological 
deficit: 
literature 
review 
Examine the 
effectiveness 
of IH to 
decrease 
neurological 
deficit 
Out-of-
hospital, 
witnessed 
cardiac arrest 
Sepsis, 
coagulo-
pathies, 
neutropenia, 
thrombocy-
topenia, 
arrhythmias, 
and electrolyte 
abnormalities 
Six studies 
showed 
improved 
outcomes 
 
Four showed 
decreased 
mortality 
 
Minimal 
complications 
exist 
Advanced 
practice nurses 
should 
promote the 
use of IH. 
 
Further 
research 
should be 
conducted on 
specific 
treatment 
protocols. 
Zhi, Zhang & 
Lin, 2003 
 
Study on 
therapeutic 
mechanism and 
clinical effect 
of mild 
hypothermia in 
patients with 
severe head 
Patients with 
acute head 
injury within 
24 hrs of 
trauma with 
major organ 
damage or 
functional 
failure 
without  
hypotension 
Severe head 
injury with a 
GCS of <8 
upon admission 
to the ED 
Effects on ICP, 
blood glucose 
and lactic acid, 
vital sign 
changes, 
namely blood 
pressure and 
heart rate, 
blood gases, 
and 
electrolytes 
IH is safe and 
effective for 
preventing brain 
damage, 
reducing 
mortality, and 
improving the 
prognosis in 
patients with 
severe head 
injury. 
IH reduced 
mortality and 
improved  
outcomes in 
patients whose 
treatment 
included IH. 
 
IH decreased 
ICP, lactic 
acid levels and 
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Author / Year 
/ Title 
Study / 
Purpose 
Population 
Studied 
Complications 
Evaluated 
Results / 
Findings 
Conclusion / 
Implications  
injury  
 
hyper-
glycemia and 
improved 
cerebral blood 
flow. 
 
No significant 
changes in 
vital signs, 
blood gas 
values, and 
electrolytes 
occurred in the 
IH group. 
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